CSPC Pharmaceutical Group (01093.HK): Phase II Clinical Trial of Albumin-bound Sirolimus for Injection Officially Launched
NewTimeSpace News: On 16 July 2026, CSPC Pharmaceutical Group (01093.HK) issued an announcement that the Phase II clinical trial of its self-developed albumin-bound sirolimus for injection, indicated for progressive or symptomatic epithelioid hemangioendothelioma, has been officially initiated at the first research center.
This product is a Class 2.2 modified new chemical drug. As a macrolide immunosuppressant and highly selective mTOR inhibitor, it exerts immunosuppressive effects by blocking the activation of the mTOR pathway.
NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.
- CSPC Pharmaceutical Group (01093.HK): Albumin-Bound Docetaxel Combined with Anitumab Granted Breakthrough Therapy Designation
- CSPC Pharmaceutical Group (01093.HK): Phase III Clinical Trial of SYS6010 Combined with Enlimomab as Adjuvant Therapy for NSCLC Officially Launched
- CSPC Pharmaceutical Group (01093.HK): Second Marketing Application for Idaglutide Alpha Injection Accepted by NMPA
- CSPC Pharmaceutical Group (01093.HK): New Drug Application for Valsartan Levoamlodipine Maleate Tablets Accepted
- CSPC Pharmaceutical Group (01093.HK): Albumin-bound Paclitaxel for Injection (II) Approved for Marketing
